NRG raises $67M to test mitochondrial pore inhibitor in ALS

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy

NRG raises $67 million for a small molecule for Parkinson’s and ALS

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS

A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try

Mitochondria: Movers and Shakers - a podcast about life with Parkinson's

Novel Parkinson’s therapy protects mitochondrial function

NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation

NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy

Case Study: Life Sciences - Future50

9 neuroscience biotech companies you should know about

MJFF grant supports NRG Therapeutics' work to validate mitochondrial drug target for Parkinson's

Case Study: R&D grant funding

Parkinson’s disease drug hunters think outside the α-synuclein box

NRG raises Series A funds for Parkinson’s and ALS therapy development

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

NRG announces £16m Series A for IND for Parkinson’s and ALS

Following the path to a new drug, together

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson's, ALS

Omega Funds leads £16m Series A round for NRG Therapeutics

NRG closes £16M series A to fund fight against neurodegenerative diseases

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup

NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment